Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3

May 18, 2026 06:34 AM EDT R&DPharma Re­gen­eron's Phase 3 skin can­cer miss adds to mount­ing fail­ures in LAG-3 Ayisha Sharma News Reporter Re­gen­eron Phar­ma­ceu­ti­cals’ LAG-3 in­hibitor called fi­an­limab has flunked a late-stage skin can­cer tri­al, mark­ing yet an­oth­er blow for the drug class. The an­nounce­ment fol­lows a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER